Lupin Diagnostics Limited (LDL), a wholly owned subsidiary of Lupin Limited, has marked a significant achievement by securing 100% NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation across all its greenfield labs. This move elevates Lupin Diagnostics to the ranks of India’s top fully accredited diagnostic chains.
“This accreditation is a testament to the team’s dedication to patient care and our mission to promote healthier lives. The 27 greenfield labs across the country ensure timely and accurate reporting. Our goal is to empower doctors and patients with evidence-based diagnostics,” said Ravindra Kumar, CEO, Lupin Diagnostics. “We remain committed to enhancing healthcare through continuous improvement and innovation.”
The NABL accreditation reinforces the diagnostic provider’s focus on delivering reliable, timely, and evidence-based diagnostics to empower doctors and patients alike. This commitment is further supported by their advanced 45,000 sq. ft. National Reference Laboratory in Navi Mumbai, which hosts over 3,000 tests across a broad spectrum of disciplines, including molecular diagnostics, microbiology, cytology, and immunology.
Lupin Diagnostics’ dedication has not gone unnoticed in the industry. The company has been honoured with several prestigious awards, such as:
These recognitions highlight the organisation’s growing influence and commitment to patient-focused diagnostics in India’s rapidly evolving healthcare ecosystem.
Read More: Lupin Arm Acquires UK-Based Renascience Pharma for ₹135 Crore
While Lupin Diagnostics celebrated its nationwide accreditation, the parent company, Lupin Limited, also shared two other key developments:
On April 17, 2025, Lupin received an Establishment Inspection Report (EIR) from the US FDA for its injectable facility in Nagpur. The report followed a successful inspection of the company’s drug-device combination product manufacturing capabilities conducted in June 2024. This marks a significant regulatory milestone, reinforcing Lupin’s capabilities in complex generics and drug-device integrations.
Separately, Lupin reported an update on its ongoing patent litigation in the US regarding its generic version of Mirabegron. On April 15, 2025, the United States District Court for the District of Delaware ruled in favour of Astellas Pharma, upholding the validity of its U.S. Patent No. 10,842,780. However, the court has scheduled a consolidated jury trial in 2026 to address further questions around patent infringement and damages. Lupin stated that the ruling currently has no material financial implications and the company remains confident in its legal position.
As of 11:35 AM on the day of the announcement, Lupin share price was trading higher by 1.55%, indicating a positive response to the NABL accreditation news and ongoing regulatory transparency.
Lupin is strategically concentrating on broadening its range of medications, developing intricate generic drugs, and increasing its research and development activities. Recent actions include launching new treatments for diabetes, gastrointestinal issues, skin conditions, and vaccines, along with pursuing strategic partnerships to strengthen its operations.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Apr 23, 2025, 2:31 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
